Skip to main content
SleepCited

Loganin Exerts Sedative and Hypnotic Effects via Modulation of the Serotonergic System and GABAergic Neurons.

Rui Shi, Yan Han, Yu Yan, Hao-Yi Qiao, Jun He et al.
Other Frontiers in pharmacology 2019 52 उद्धरण
PubMed DOI PDF
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D31068813'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

अध्ययन प्रकार
In Vitro
हस्तक्षेप
Loganin Exerts Sedative and Hypnotic Effects via Modulation of the Serotonergic System and GABAergic Neurons. 20-50 mg/kg (sedative effect in mice); 35 mg/kg (EEG/EMG in rats)
तुलनित्र
Placebo
प्रभाव की दिशा
Positive
पूर्वाग्रह का जोखिम
Unclear

Abstract

Corni fructus, the fruit of Cornus officinalis Sieb. et Zucc., has been used as a tonic for the kidney in China for thousands of years. Loganin is one of the major constituents derived from Corni fructus. In this study, we revealed the sedative and hypnotic activity of loganin and investigated its mechanisms for the first time. Pentobarbital-induced sleep test and insomnia mice models [induced by caffeine and p-chlorophenylalanine (PCPA)] were used for the assessment of sedative and hypnotic effects of loganin. It was found that loganin (20-50 mg/kg) exerted sedative effect in normal mice. Loganin exhibited hypnotic effect by increasing sleep onset and sleep duration in pentobarbital-treated mice, recovering PCPA-induced insomnia and exerting synergistic hypnosis effect with 5-HTP. In addition, electroencephalograph (EEG) and electromyography (EMG) recordings of rats showed that loganin (35 mg/kg) prolonged the ratio of non-rapid eye movement (NREM) sleep and shortened wakefulness significantly, further immunohistochemistry showed that loganin (35 mg/kg) increased c-Fos expression in GABAergic neurons of rats in the ventrolateral preoptic nucleus (VLPO). The levels of norepinephrine (NE), dopamine (DA), serotonin (5-HT) and its metabolite were measured in the hippocampus, prefrontal cortex and striatum of mice, 1 h after loganin (35 mg/kg) treatment. 5-HT, 5-HIAA/5-HT, DA, and DOPAC were decreased significantly in the prefrontal cortex. In conclusion, these results indicated that loganin produced beneficial sedative and hypnotic activity, which might be mainly mediated by modification of the serotonergic system and GABAergic neurons.

Full Text

PDF
Loading PDF...

Figures

Experimental design for testing loganin's sedative and hypnotic effects in mice models, including pentobarbital-induced sleep and insomnia paradigms.

FIGURE 1

Experimental design for testing loganin's sedative and hypnotic effects in mice models, including pentobarbital-induced sleep and insomnia paradigms.

diagram
Pentobarbital-induced sleep test results demonstrate that loganin administration significantly altered sleep onset latency and total sleep duration in mice.

FIGURE 2

Pentobarbital-induced sleep test results demonstrate that loganin administration significantly altered sleep onset latency and total sleep duration in mice.

chart
Dose-response analysis of loganin's hypnotic effects in the pentobarbital sleep model reveals concentration-dependent changes in sleep parameters.

FIGURE 3

Dose-response analysis of loganin's hypnotic effects in the pentobarbital sleep model reveals concentration-dependent changes in sleep parameters.

chart
Loganin's effects on serotonergic system markers, including 5-HT levels and receptor expression in the brain, are quantified in treated versus control mice.

FIGURE 4

Loganin's effects on serotonergic system markers, including 5-HT levels and receptor expression in the brain, are quantified in treated versus control mice.

chart
GABAergic neuron activity measurements show that loganin modulates GABA receptor signaling, contributing to its observed sedative properties.

FIGURE 5

GABAergic neuron activity measurements show that loganin modulates GABA receptor signaling, contributing to its observed sedative properties.

chart
Immunohistochemical or western blot analysis of c-Fos expression in sleep-promoting brain regions following loganin treatment indicates enhanced neuronal activation.

FIGURE 6

Immunohistochemical or western blot analysis of c-Fos expression in sleep-promoting brain regions following loganin treatment indicates enhanced neuronal activation.

chart
Neurotransmitter level quantification in key brain regions demonstrates that loganin treatment alters the balance of serotonin and GABA pathways associated with sleep regulation.

FIGURE 7

Neurotransmitter level quantification in key brain regions demonstrates that loganin treatment alters the balance of serotonin and GABA pathways associated with sleep regulation.

chart
Behavioral analysis in insomnia mouse models shows that loganin reverses sleep disturbances induced by p-chlorophenylalanine, suggesting serotonergic involvement.

FIGURE 8

Behavioral analysis in insomnia mouse models shows that loganin reverses sleep disturbances induced by p-chlorophenylalanine, suggesting serotonergic involvement.

chart
Proposed mechanism of action diagram illustrates how loganin from Corni fructus exerts sedative and hypnotic effects through dual modulation of the serotonergic system and GABAergic neurons.

FIGURE 9

Proposed mechanism of action diagram illustrates how loganin from Corni fructus exerts sedative and hypnotic effects through dual modulation of the serotonergic system and GABAergic neurons.

diagram

Tables

Table 1

GroupsDosage (mg/kg, i.g.)No. of falling asleep/totalSleep onset (%)
Vehicle1/254.0
Estazolam0.1525/25100.0
Loganin59/2536.0
2015/2560.0
5015/2560.0

Table 2

GroupsDosage (mg/kg)No. of falling asleep/totalSleep onset (%)
Vehicle0/120.0
5-HTP2.5 (i.p.)2/1216.7
Loganin5 (i.g.)2/1216.7
5-HTP + Loganin2.5 (i.p.) +5 (i.g.)12/1291.67∗∗

Table 3

GroupNE (ng/g)5-HT (ng/g)5-HIAA (ng/g)DA (ng/g)DOPAC (ng/g)5-HIAA/5-HTDOPAC/DA
PFCControl673.5 ± 119.11115 ± 151.4337.5 ± 49.211031 ± 698.4417.3 ± 145.40.29 ± 0.020.58 ± 0.18
Loganin469.5 ± 72.33687.7 ± 91.16241.3 ± 40.44223.8 ± 56.61∗∗124.7 ± 8.557∗∗0.35 ± 0.050.63 ± 0.071
STRControl263 ± 64.29466.8 ± 99.63322.1 ± 73.2116052 ± 36931088 ± 190.40.78 ± 0.140.09 ± 0.005
Loganin265.6 ± 26.61723 ± 80.8605.2 ± 92.0715287 ± 16451284 ± 125.50.80 ± 0.070.09 ± 0.003
HIPControl478.4 ± 78.22445.6 ± 61.47346.8 ± 84.6666.42 ± 16.19ND0.60 ± 0.10ND
Loganin515.9 ± 68.09499.3 ± 62.03382.7 ± 98.1675.44 ± 29.22ND0.59 ± 0.11ND

References

  1. Untitled
  2. Untitled
  3. Untitled
  4. Untitled
  5. Untitled
  6. Untitled
  7. Untitled
  8. Untitled
  9. Untitled
  10. Untitled
  11. Untitled
  12. Untitled
  13. Untitled
  14. Untitled
  15. Untitled
  16. Untitled
  17. Untitled
  18. Untitled
  19. Untitled
  20. Untitled
  21. Untitled
  22. Untitled
  23. Untitled
  24. Untitled
  25. Untitled

Used In Evidence Reviews

Similar Papers